Literature DB >> 18472827

Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases.

P Vergne1, V Praloran, R Treves, Y Denizot.   

Abstract

PAF is a potent inflammatory compound known to stimulate the release of various cytokines involved in rheumatic diseases. Elevated blood PAF levels are reported in these patients. We report that serum PAF acetylhydrolase activity (AHA) levels are decreased in patients with rheumatoid arthritis or osteoarthritis as compared to healthy controls. Serum and synovial fluid AHA levels were correlated in these patients. The present study suggests the potential role of AHA in controling systemic and/or local PAF levels in patients with rheumatic diseases.

Entities:  

Year:  1997        PMID： 18472827      PMCID： PMC2365831          DOI： 10.1080/09629359791758

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN： 0962-9351            Impact factor:   4.711


  13 in total

1.  Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.

Authors:  A Dulioust; P Hilliquin; C J Menkes; J Benveniste; B Arnoux
Journal:  Scand J Rheumatol       Date:  1992       Impact factor: 3.641

Review 2.  Mammalian platelet-activating factor acetylhydrolases.

Authors:  D M Stafforini; S M Prescott; G A Zimmerman; T M McIntyre
Journal:  Biochim Biophys Acta       Date:  1996-06-11

3.  Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children.

Authors:  M Miwa; T Miyake; T Yamanaka; J Sugatani; Y Suzuki; S Sakata; Y Araki; M Matsumoto
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

4.  Decreased levels of platelet-activating factor in blood of patients with lymphoid and nonlymphoid hematologic malignancies.

Authors:  Y Denizot; F Dupuis; F Trimoreau; V Praloran; E Liozon
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

5.  Elevated levels of paf-acether in blood of patients with type 1 diabetes mellitus.

Authors:  N Nathan; Y Denizot; M C Huc; C Claverie; B Laubie; J Benveniste; B Arnoux
Journal:  Diabete Metab       Date:  1992 Jan-Feb

Review 6.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

7.  Presence of paf-acether in rheumatic diseases.

Authors:  P Hilliquin; C J Menkes; S Laoussadi; J Benveniste; B Arnoux
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

8.  The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease).

Authors:  P H Pritchard; A Chonn; C C Yeung
Journal:  Blood       Date:  1985-12       Impact factor: 22.113

9.  Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease.

Authors:  K Satoh; T Imaizumi; Y Kawamura; H Yoshida; S Takamatsu; S Mizono; B Shoji; M Takamatsu
Journal:  Prostaglandins       Date:  1988-05

10.  Eicosanoid and cytokine levels in plasma of patients during mesenteric infarction.

Authors:  N Nathan; Y Denizot; P Feiss
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711
View more
  1 in total

1.  Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B.

Authors:  Limin Feng; Ying Zhao; Guofang Feng; Yu Chen
Journal:  Lipids Health Dis       Date:  2014-06-28       Impact factor: 3.876
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.